# An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy

> **NCT04157257** · PHASE2 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** TDF tablet
- **DRUG:** Entecavir Tablet
- **DRUG:** QL-007

## Key facts

- **NCT ID:** NCT04157257
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-26
- **Primary completion:** 2020-12
- **Final completion:** 2022-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04157257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04157257, "An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04157257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*